(Q42686882)

4 November 2017

Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model (English)

1 reference

cost-effectiveness analysis

4 November 2017

1 reference

0 references

Kobelt G

1

1 reference

PubMed ID

9829424

4 November 2017

Jönsson L

series ordinal

2

1 reference

PubMed ID

9829424

4 November 2017

Mattiasson A

series ordinal

3

1 reference

4 November 2017

1 January 1998

1 reference

Neurourology and Urodynamics

4 November 2017

1 reference

4 November 2017

17

1 reference

4 November 2017

6

1 reference

4 November 2017

599-611

1 reference

EuroQol--a new facility for the measurement of health-related quality of life

4 November 2017

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-6777%281998%2917%3A6%3C599%3A%3AAID-NAU4%3E3.0.CO%3B2-J

The quality of life in women with urinary incontinence as measured by the sickness impact profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-6777%281998%2917%3A6%3C599%3A%3AAID-NAU4%3E3.0.CO%3B2-J

Economic considerations and outcome measurement in urge incontinence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-6777%281998%2917%3A6%3C599%3A%3AAID-NAU4%3E3.0.CO%3B2-J

A review of the quality-of-life aspects of urinary urge incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-6777%281998%2917%3A6%3C599%3A%3AAID-NAU4%3E3.0.CO%3B2-J

Cost-per-QALY league tables: their role in pharmacoeconomic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-6777%281998%2917%3A6%3C599%3A%3AAID-NAU4%3E3.0.CO%3B2-J

Markov models in medical decision making: a practical guide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-6777%281998%2917%3A6%3C599%3A%3AAID-NAU4%3E3.0.CO%3B2-J

Psychosocial impact of urinary incontinence in the community-dwelling population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-6777%281998%2917%3A6%3C599%3A%3AAID-NAU4%3E3.0.CO%3B2-J

Willingness to pay for reduced incontinence symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-6777%281998%2917%3A6%3C599%3A%3AAID-NAU4%3E3.0.CO%3B2-J

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-6777%281998%2917%3A6%3C599%3A%3AAID-NAU4%3E3.0.CO%3B2-J

A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-6777%281998%2917%3A6%3C599%3A%3AAID-NAU4%3E3.0.CO%3B2-J

10.1002/(SICI)1520-6777(1998)17:6<599::AID-NAU4>3.0.CO;2-J

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference

PubMed ID

9829424